RBC Capital analyst Ben Hendrix raised the firm’s price target on UnitedHealth (UNH) to $408 from $286 and keeps an Outperform rating on the shares after its Q3 earnings beat. The management voiced confidence in pricing actions and plan exits driving margin expansion across the enterprise next year, the analyst tells investors in a research note. With expectations of margin improvement accelerating in 2027, UnitedHealth should see EPS growth near the low-end of its long-term annual EPS growth target of 13%-16%, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target raised to $415 from $325 at Oppenheimer
- UnitedHealth price target raised to $410 from $390 at BofA
- UnitedHealth price target lowered to $417 from $423 at Piper Sandler
- Enrollees of ACA plans learn of hefty premium increases, WSJ reports
- Deutsche Bank downgrades UnitedHealth to Hold on valuation